Stephens resumed coverage on Bio-Techne with a new price target
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stephens resumed coverage of Bio-Techne with a rating of Overweight and set a new price target of $65.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/11/2026 | $65.00 | Neutral | Piper Sandler |
| 5/15/2026 | $62.00 | Outperform | RBC Capital Mkts |
| 9/3/2025 | $73.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 8/21/2025 | $70.00 | Neutral → Buy | Citigroup |
| 7/22/2025 | $65.00 | Overweight | Stephens |
| 7/9/2025 | $65.00 | Buy | TD Cowen |
| 5/30/2025 | $59.00 | Overweight | Wells Fargo |
| 4/9/2025 | Overweight → Sector Weight | KeyBanc Capital Markets |
DEFA14A - BIO-TECHNE Corp (0000842023) (Filer)
8-K - BIO-TECHNE Corp (0000842023) (Filer)
DEFA14A - BIO-TECHNE Corp (0000842023) (Filer)
Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture WorkflowsNew heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&D Systems™ AI-Engineered Designer Protein portfolioAI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflowsEngineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturingMINNEAPOLIS, July 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D
Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion)Proposed acquisition expected to be immediately accretive to sales growth and EBITDA pre margin post-closing, and EPS pre accretive by year 3 after closingU.S.-based Bio-Techne to bring portfolio with industry-leading multi-omics offering, analytical technologies and integrated workflow solutions across the scientific journeyWould deliver on growth agenda of Merck KGaA, Darmstadt, Germany, by expanding presence in high-growth, next-generation life sciences markets and further strengthening the position as a leader along the full life science value chainWould add complementary strength
New integrated workflow combines icIEF fractionation and mass photometryEnables direct characterization of aggregation and size within icIEF-resolved charge variantsFour-hour workflow reduces development risk and accelerates biosimilar manufacturingMINNEAPOLIS and OXFORD, England, June 4, 2026 /PRNewswire/ -- Bio‑Techne Corporation (NASDAQ:TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first‑of‑its‑kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars.By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focu
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
Piper Sandler initiated coverage of Bio-Techne with a rating of Neutral and set a new price target of $65.00
RBC Capital Mkts resumed coverage of Bio-Techne with a rating of Outperform and set a new price target of $62.00
RBC Capital Mkts upgraded Bio-Techne from Sector Perform to Outperform and set a new price target of $73.00
Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion)Proposed acquisition expected to be immediately accretive to sales growth and EBITDA pre margin post-closing, and EPS pre accretive by year 3 after closingU.S.-based Bio-Techne to bring portfolio with industry-leading multi-omics offering, analytical technologies and integrated workflow solutions across the scientific journeyWould deliver on growth agenda of Merck KGaA, Darmstadt, Germany, by expanding presence in high-growth, next-generation life sciences markets and further strengthening the position as a leader along the full life science value chainWould add complementary strength
MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2026. The quarterly dividend will be payable May 29, 2026, to all common shareholders of record on May 18, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.Bio–Techne Corporation (NASDAQ:TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high–quality reagents, analytical instruments, and precision diagnostics. Its portfo
MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ending March 31, 2026.Third Quarter FY2026 HighlightsReported and organic revenue declined 2% to $311.4M, negatively impacted by prior‑year GMP fast‑track orders and timing of large Commercial Supply shipmentsGAAP EPS increased to $0.32 from $0.14; adjusted EPS was $0.53, down from $0.56Large pharma delivered the sixth consecutive quarter of double‑digit growth, offset by a continued lag in spending by emerging biotech; U.S. academic markets stabilized with low‑single‑digit growthGrowth vectors performed well, with mid‑single‑digit growth in Proteomic Analy
SC 13G - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining th
MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s
MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D